厄洛替尼与培美曲塞治疗晚期非小细胞肺癌疗效的间接比较

Indirect Comparisons for the Efficacy of Erlotinib and Pemetrexed in Patients with Nonsmall Cell Lung Cancer

目的:根据临床研究文献,采用间接比较的方法综合评价厄洛替尼与培美曲塞治疗晚期非小细胞肺癌的临床疗效。方法:计算机检索国内外公开发表的关于厄洛替尼或培美曲塞治疗晚期非小细胞肺癌的中英文文献,采RevMan5.0和ITC软件对纳入的研究进行间接比较。结果:共纳入7项吉非替尼vs厄洛替尼和7项吉非替尼vs培美曲塞的文献进行间接比较。厄洛替尼与培美曲塞治疗晚期非小细胞肺癌的有效率和疾病控制率的RR值分别为1.11(P=0.40)、1.12(P=0.69)。结论:厄洛替尼和培美曲塞治疗晚期非小细胞肺癌的疗效无显著性差异,但二者的临床有效性尚需要更多高质量的大规模随机对照研究来进行证实。

Objective： To systematically evaluate the efficacy of Erlotinib and Pemetrexed in patients with non-small cell lung cancer （NSCLC）.Methods： The related literature concerning the clinical trials of Erlotinib or /and Pemetrexed in the treatment of non-small cell lung cancer published both in the domestic area and overseas literature between 2005 and 2013 were retrieved. Meta analysis on of the selected literature was conducted by means of Review Manager 5.0 and ITC software.Results： A total of 12 clinical trials were included in our study. The RR of overall response rate and disease control rate between Erlotinib and and Pemetrexed Pemetrexed in in patients patients with with NSCLC NSCLC were were 1.11（P=0.40） and 1.12（P=0.69）.Conclusion： No profound significant differences were found in efficacy between Erlotinib and Pemetrexed in patients with NSCLC. However, the results should be interpreted with caution because of the quantity and sample size of the included trials. More higher quality studies are needed to further prove the results.